Thompson Davis & CO. Inc. Purchases Shares of 29,750 Chromadex Corp (CDXC)
Thompson Davis & CO. Inc. purchased a new stake in Chromadex Corp (OTCMKTS:CDXC) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 29,750 shares of the company’s stock, valued at approximately $128,000. Thompson Davis & CO. Inc. owned about 0.06% of Chromadex Corp as of its most recent SEC filing.
Several other institutional investors have also made changes to their positions in CDXC. North Star Investment Management Corp. increased its holdings in Chromadex Corp by 78.9% during the 2nd quarter. North Star Investment Management Corp. now owns 265,334 shares of the company’s stock worth $1,014,000 after purchasing an additional 117,000 shares during the period. Goldman Sachs Group Inc. increased its holdings in Chromadex Corp by 870.6% during the 2nd quarter. Goldman Sachs Group Inc. now owns 182,633 shares of the company’s stock worth $698,000 after purchasing an additional 163,817 shares during the period. LMR Partners LLP purchased a new stake in Chromadex Corp during the 2nd quarter worth about $347,000. Finally, Bank of Montreal Can purchased a new stake in Chromadex Corp during the 2nd quarter worth about $168,000.
CDXC has been the topic of a number of research reports. HC Wainwright set a $5.00 price target on Chromadex Corp and gave the stock a “buy” rating in a research note on Friday, August 11th. Ladenburg Thalmann Financial Services started coverage on Chromadex Corp in a research report on Monday, September 25th. They set a “buy” rating and a $7.00 price objective for the company. ValuEngine raised Chromadex Corp from a “sell” rating to a “hold” rating in a research report on Friday, September 8th. Finally, Zacks Investment Research cut Chromadex Corp from a “hold” rating to a “sell” rating in a research report on Monday, July 17th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. Chromadex Corp currently has a consensus rating of “Hold” and an average price target of $6.33.
COPYRIGHT VIOLATION NOTICE: “Thompson Davis & CO. Inc. Purchases Shares of 29,750 Chromadex Corp (CDXC)” was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://theolympiareport.com/2017/11/02/thompson-davis-co-inc-purchases-shares-of-29750-chromadex-corp-cdxc.html.
In other news, major shareholder Step Holdings Ltd Pioneer acquired 786,167 shares of the company’s stock in a transaction dated Friday, August 18th. The stock was bought at an average price of $2.60 per share, with a total value of $2,044,034.20. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Robert N. Fried acquired 10,000 shares of the company’s stock in a transaction dated Tuesday, August 15th. The shares were purchased at an average cost of $3.15 per share, with a total value of $31,500.00. Following the acquisition, the insider now owns 583,241 shares of the company’s stock, valued at approximately $1,837,209.15. The disclosure for this purchase can be found here. Insiders have acquired 798,167 shares of company stock valued at $2,082,154 over the last 90 days.
Chromadex Corp (OTCMKTS:CDXC) last released its quarterly earnings results on Thursday, August 10th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.04 by ($0.09). Chromadex Corp had a negative net margin of 52.09% and a negative return on equity of 63.19%. The firm had revenue of $5.31 million for the quarter, compared to the consensus estimate of $11.00 million.
Chromadex Corp Profile
Chromadex Corporation and its subsidiaries ChromaDex, Inc, ChromaDex Analytics, Inc and Spherix Consulting, Inc provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets.
Want to see what other hedge funds are holding CDXC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chromadex Corp (OTCMKTS:CDXC).
Receive News & Ratings for Chromadex Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.